Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01522976
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:06.340947+00:00
Published At
2016-03-22T00:00:00+00:00
Record Updated At
2026-03-31
Results Posted At
2016-03-22
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Chronic Myelomonocytic Leukemia", "Chronic Myelomonocytic Leukemia-1", "Chronic Myelomonocytic Leukemia-2", "Myelodysplastic Syndrome", "Myelodysplastic Syndrome With Excess Blasts", "Myelodysplastic Syndrome With Excess Blasts-1", "Myelodysplastic Syndrome/Acute Myeloid Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-03-31"
protocolSection.identificationModule.nctId
"NCT01522976"
protocolSection.identificationModule.officialTitle
"A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2016-03-22"

Study condition terms

  • Chronic Myelomonocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Chronic Myelomonocytic Leukemia-1 (protocolSection.conditionsModule.conditions)
  • Chronic Myelomonocytic Leukemia-2 (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndrome With Excess Blasts (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndrome With Excess Blasts-1 (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndrome/Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.